These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39382899)

  • 21. Medical device recalls and the FDA approval process.
    Zuckerman DM; Brown P; Nissen SE
    Arch Intern Med; 2011 Jun; 171(11):1006-11. PubMed ID: 21321283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings.
    White SK; Leiter V; Le MH; Helms CK
    PLoS One; 2023; 18(2):e0281774. PubMed ID: 36795788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. United States Food and Drug Administration Advisory Committee outcomes and agency approval analysis from 2010 to 2015.
    McCormack Z
    J Am Pharm Assoc (2003); 2018; 58(5):530-533. PubMed ID: 30005816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pivotal trials of orthopedic surgical devices in the United States: predominance of two-arm non-inferiority designs.
    Golish SR
    Trials; 2017 Jul; 18(1):348. PubMed ID: 28738891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical Devices Applying for Outpatient Medicare Supplemental Payments.
    Moneer O; Johnston JL; Rathi VK; Ross JS; Dhruva SS
    JAMA Health Forum; 2024 Nov; 5(11):e244016. PubMed ID: 39546305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
    Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
    JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System.
    Loh JP; Barbash IM; Waksman R
    J Am Coll Cardiol; 2013 Apr; 61(15):1571-6. PubMed ID: 23352783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications.
    Tau N; Shepshelovich D
    JAMA Intern Med; 2020 Nov; 180(11):1420-1426. PubMed ID: 32986074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The FDA process for the evaluation and approval of orthopaedic devices.
    Kirkpatrick JS; Stevens T
    J Am Acad Orthop Surg; 2008 May; 16(5):260-7. PubMed ID: 18460686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC).
    Ayon Verduzco A; Yeboah K
    Ther Innov Regul Sci; 2021 Jan; 55(1):98-110. PubMed ID: 32767033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    JAMA; 2009 Dec; 302(24):2679-85. PubMed ID: 20040556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory aspects of noninvasive glucose measurements.
    Gutman S; Bernhardt P; Pinkos A; Moxey-Mims M; Knott T; Cooper J
    Diabetes Technol Ther; 2002; 4(6):779-81. PubMed ID: 12685801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pivotal clinical trials with patient-reported outcome measures in premarket approval applications for high-risk medical devices from 2005 to 2018: Review, examples, and regulatory considerations.
    Zhang B; Shankara SB; Guo J; Zhang H
    Contemp Clin Trials; 2022 May; 116():106757. PubMed ID: 35398250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice.
    Deyo RA
    J Am Board Fam Pract; 2004; 17(2):142-9. PubMed ID: 15082674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
    Ronquillo JG; Zuckerman DM
    Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An ESHG-ESHRE survey on the current practice of expanded carrier screening in medically assisted reproduction.
    Capalbo A; de Wert G; Henneman L; Kakourou G; Mcheik S; Peterlin B; van El C; Vassena R; Vermeulen N; Viville S; Forzano F
    Hum Reprod; 2024 Aug; 39(8):1844-1855. PubMed ID: 38872341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.